Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

February 13, 2019

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the potential for immunotherapy beyond PD-1 and PD-L1 checkpoints in non–small cell lung cancer.

January 28, 2019

Amol K. Narang, MD, discusses recent advances made in the treatment of pancreatic cancer and explained how radiation oncology can be used to provide further clinical benefit to this patient population.

December 27, 2018

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

September 10, 2018

Matthew Ladra, MD, MPH, discusses the treatment of patients with esthesioneuroblastoma, emphasizing the need for collaboration in this rare malignancy.

September 06, 2018

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses targetable immune checkpoints in head and neck squamous cell carcinoma.

July 12, 2018

Matthew Ladra, MD, director, Pediatric Radiation Oncology, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, discusses the treatment of esthesioneuroblastoma in children.

June 28, 2018

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the immunosuppressive microenvironment of nasopharyngeal cancer.

June 09, 2018

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

May 25, 2018

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses the potential for combination immunotherapy in the treatment of patients with head and neck cancer.

April 24, 2018

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.

April 21, 2018

Amy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.

April 19, 2018

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the treatment of patients with nasopharyngeal carcinoma.

March 15, 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer.

April 18, 2017

Julie R. Brahmer, MD, discusses the 5-year findings of nivolumab in non-small cell lung cancer, their significance, and expected next steps for this research.

February 08, 2017

Anne Rositch, PhD, discusses important takeaways from her study on hysterectomy-corrected mortality rates in cervical cancer and the significance of cervical cancer screening.

February 07, 2017

Cynthia L. Sears, MD, professor of Medicine, Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses bacteria possibly influencing the development of colon cancer.

January 28, 2017

Cynthia L. Sears, MD, professor of Medicine, at John Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses microbiota in patients with colon cancer.

October 31, 2016

​Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discusses the role of the PD-L1 biomarker and other biomarkers on the horizon for the use in immunotherapy.

September 14, 2016

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the eventual role that immunotherapy will play in the treatment landscape of renal cell carcinoma (RCC), as well as patient selection to receive immunotherapy as a single agent or in combination.

April 26, 2016

Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.